2556837-25-1
Chemical Structure
DCZ3112
- CAS No.: 2556837-25-1
- Formula:C15H14ClF3N8
- Molecular Weight:398.78
IUPAC Name: (Z)-N-(4-chloro-3-(trifluoromethyl)phenyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-4-hydrazono-1,4-dihydro-1,3,5-triazin-2-amine
InChIKey: CBURLVUZHNXWGR-UHFFFAOYSA-N
SMILES: FC(F)(F)C1=CC(=CC=C1Cl)NC2=NC(=NN)N=C(N2)N3N=C(C=C3C)C
Biological Activity: DCZ3112 is a Hsp90/Cdc37 protein-protein interaction inhibitor, with a Kd value of 4.98 µM against human Hsp90. DCZ3112 binds to the N-terminal domain of Hsp90, disrupts the Hsp90-Cdc37 interaction, and does not inhibit the ATPase activity of Hsp90. DCZ3112 induces G1 phase cell cycle arrest, apoptosis, reduces the phosphorylation levels of AKT and ERK, and inhibits the proliferation of HER2-positive breast cancer cells. DCZ3112 can be used in breast cancer-related research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DCZ3112 | DCZ3112 is a Hsp90/Cdc37 protein-protein interaction inhibitor, with a Kd value of 4.98 µM against human Hsp90. DCZ3112 binds to the N-terminal domain of Hsp90, disrupts the Hsp90-Cdc37 interaction, and does not inhibit the ATPase activity of Hsp90. DCZ3112 induces G1 phase cell cycle arrest, apoptosis, reduces the phosphorylation levels of AKT and ERK, and inhibits the proliferation of HER2-positive breast cancer cells. DCZ3112 can be used in breast cancer-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen X, et al. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction. Cancer Lett. 2018 Oct 10;434:70-80.
- [2]. Kamel EM, et al. Disrupting the Hsp90-Cdc37 axis: a selective strategy for targeting oncogenic kinases in cancer. RSC advances. 2025 Jun 04;15(24):19376-19391.
- [3]. Lu H, et al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5(1):213. [Content Brief]
